[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Barney BM, MacDonald OK, Lee CM, Rankin J, Gaffney DK: An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer. Brachytherapy; 2007 Jul-Sep;6(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer.
  • Our primary endpoint was to assess the significance of simulation in women who received adjuvant intracavitary high-dose-rate brachytherapy (HDR-BT) for early-stage endometrial adenocarcinoma.
  • Secondary endpoints included assessment of acute and late treatment toxicity, medication requirements, and charges related to the HDR-BT simulation and procedure.
  • METHODS AND MATERIALS: Twenty-four consecutive women with early-stage endometrial cancer treated with adjuvant HDR-BT were evaluated.
  • Data on acute and late toxicities, medication usage, and simulation charges were evaluated and compared.
  • No substantial deviation in the means of the calculated ratios was observed except at the bladder point (mean 0.77+/-0.23).
  • Half of the women required prescription medication incident to simulation.
  • CONCLUSIONS: Despite the broad range of doses calculated at the bladder point, genitourinary toxicity was minimal.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Endometrial Neoplasms / radiotherapy. Postoperative Care / methods. Radiotherapy Planning, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681241.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Kim CW, Kim JH, Yu CS, Shin US, Park JS, Jung KY, Kim TW, Yoon SN, Lim SB, Kim JC: Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):156-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There was no between-group difference in age, gender, or cancer stage.
  • [MeSH-major] Adenocarcinoma. Anal Canal / surgery. Neoadjuvant Therapy / methods. Postoperative Complications / etiology. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Enteritis / etiology. Enteritis / surgery. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Ileostomy / statistics & numerical data. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Korea. Leucovorin / administration & dosage. Male. Middle Aged. Multivariate Analysis. Preoperative Care. Radiotherapy Dosage. Rectal Fistula / etiology. Rectal Fistula / surgery. Rectovaginal Fistula / etiology. Rectovaginal Fistula / therapy. Rectum / surgery. Urinary Bladder Fistula / etiology. Urinary Bladder Fistula / surgery. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20106604.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol; 2005 Jul;174(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.
  • PURPOSE: Primary neuroendocrine tumors of the bladder are rare and they include small and large cell variants.
  • MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer at our institution, of whom 25 (1.2%) had neuroendocrine tumors of the bladder, including small cell carcinoma in 20 and large cell carcinoma in 5.
  • Pure neuroendocrine-type histology was identified in 16 cases, including 1 with small and large cell features, while the remaining 9 had mixed histology, that is transitional cell carcinoma in 8 and adenocarcinoma in 1.
  • Multi-agent chemotherapy was administered to 14 patients.
  • CONCLUSIONS: Neuroendocrine tumors of the bladder usually present with advanced pathological stage and portend a poor prognosis.
  • [MeSH-major] Cystectomy / methods. Neuroendocrine Tumors / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947585.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Chen Y, Xu H, Li Y, Wang D, Li J, Yuan J, Liang Z: The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients. Ann Surg Oncol; 2008 Oct;15(10):2847-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other medical problems included 47 cases (15.9%) of bladder dysfunction and 62 cases (21.0%) of rectum dysfunction or constipation.
  • With more experience it is envisaged that IIb stage patients can be managed safely offering all the benefits of minimal surgery to the patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / pathology. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome


5. Kotake M, Murakami N, Bandou H, Morita K, Koizumi H, Yoshino H, Tawaraya K, Ishiguro K, Kinoshita S, Yamada T: [A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1955-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the resected material a 5 x 4 cm type 2 tumor was identified.
  • Pathological findings included poorly-differentiated adenocarcinoma, si (bladder), n 4, P 0, ly 3, v 3, H 0, M(-), Stage IV.
  • TS-1(80 mg/body/day) orally administered for 4 weeks followed by a drug-free 2-week period as one course.
  • There were no drug side effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small. Lymph Nodes / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


6. Xiao Z, Tamimi Y, Brown K, Tulip J, Moore R: Interstitial photodynamic therapy in subcutaneously implanted urologic tumors in rats after intravenous administration of 5-aminolevulinic acid. Urol Oncol; 2002 May-Jun;7(3):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) may be an attractive option for treatment of early stage prostate cancer.
  • We investigated the efficacy of ALA-mediated PDT for rat R3327-H prostate cancer, compared with the AY-27 bladder tumor.
  • At the day of PDT, animals were administered 500 mg/kg ALA intravenously 4 hours prior to laser therapy.
  • Animals bearing R3327-H tumors were imaged with 99mTc-HMPAO scintigraphy to evaluate tumor perfusion changes induced by PDT.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use. Prostatic Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radionuclide imaging. Animals. Male. Rats. Rats, Inbred F344. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12474546.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


7. Guichard G, Rebibou JM, Ducloux D, Simula-Faivre D, Tiberghien P, Chalopin JM, Bittard H, Saas P, Kleinclauss F: Lymphocyte subsets in renal transplant recipients with de novo genitourinary malignancies. Urol Int; 2008;80(3):257-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte subsets in renal transplant recipients with de novo genitourinary malignancies.
  • INTRODUCTION: The incidence of genitourinary tumors (GUT) in renal transplant recipients (RTR) is higher than in the general population.
  • RESULTS AND CONCLUSION: During the follow-up period, 13 patients developed GUT: 6 patients a prostate adenocarcinoma (incidence 0.06%/year) and 7 patients a renal cell carcinoma (incidence 0.07%/year).
  • This suggests that other factors encountered in the setting of kidney transplantation (e.g., immunosuppressive drugs, end-stage renal failure, etc.) favor the development of GUT in RTR.
  • [MeSH-major] CD4-Positive T-Lymphocytes. Carcinoma, Renal Cell / blood. Kidney Neoplasms / blood. Kidney Transplantation / adverse effects. Lymphopenia / etiology. Prostatic Neoplasms / blood. T-Lymphocyte Subsets. Urinary Bladder Neoplasms / blood






Advertisement